Immunotherapy of advanced renal cell carcinoma: Current and future therapies

被引：13

作者：

Gill, David ^{[1
]}

Hahn, Andrew W. ^{[1
]}

Sonpavde, Guru ^{[2
]}

Agarwal, Neeraj ^{[3
]}

机构：

[1] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA

[2] Univ Alabama Birmingham, Birmingham, AL USA

[3] Huntsman Canc Inst, Salt Lake City, UT USA

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2016年 / 12卷 / 12期

关键词：

advanced renal cell carcinoma; cytokines; checkpoint inhibitors; immunotherapy; HIGH-DOSE INTERLEUKIN-2; BEVACIZUMAB PLUS INTERFERON; REGULATORY T-CELLS; RECOMBINANT INTERLEUKIN-2; METASTATIC MELANOMA; IMMUNE-SYSTEM; EVEROLIMUS; COMBINATION; CTLA-4; ALPHA;

D O I：

10.1080/21645515.2016.1212794

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Previously a malignancy with few therapeutic options, metastatic renal cell carcinoma (mRCC) treatment is rapidly evolving. Although cytokine therapies (interferon-a, interleukin-2) have been used less frequently over the past decade, recent approval of an immune checkpoint inhibitor, nivolumab, has led to a resurgence in immune therapy for mRCC. With greater understanding of the complex and dynamic interaction between the tumor and the immune system numerous new immunotherapies are being studied for mRCC. In this article, we review the mechanism of action, clinical outcomes and toxicity profiles of both clinically approved and selected investigational immunotherapies. Either alone or in combination, these novel agents are encouraging for the future of mRCC therapy.

引用

页码：2997 / 3004

页数：8

共 76 条

[1] Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results [J].

Amin, Asim ;

Dudek, Arkadiusz Z. ;

Logan, Theodore F. ;

Lance, Raymond S. ;

Holzbeierlein, Jeffrey M. ;

Knox, Jennifer J. ;

Master, Viraj A. ;

Pal, Sumanta K. ;

Miller, Wilson H., Jr. ;

Karsh, Lawrence I. ;

Tcherepanova, Irina Y. ;

DeBenedette, Mark A. ;

Williams, W. Lee ;

Plessinger, Douglas C. ;

Nicolette, Charles A. ;

Figlin, Robert A. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3

[2] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). [J].

Amin, Asim ;

Plimack, Elizabeth R. ;

Infante, Jeffrey R. ;

Ernstoff, Marc S. ;

Rini, Brian I. ;

McDermott, David F. ;

Knox, Jennifer J. ;

Pal, Sumanta Kumar ;

Voss, Martin Henner ;

Sharma, Padmanee ;

Kollmannsberger, Christian K. ;

Heng, Daniel Yick Chin ;

Spratlin, Jennifer L. ;

Shen, Yun ;

Kurland, John F. ;

Gagnier, Paul ;

Hammers, Hans J. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[3]

[Anonymous], 2016, J CLIN ONCOL, DOI DOI 10.1200/JCO.2016.34.2_SUPPL.559

[4]

Atkins M B GS., 2015, JImmunotherapy of Cancer, V3, P1

[5] Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study. [J].

Atkins, Michael B. ;

Choueiri, Toni K. ;

Hodi, F. Stephen ;

Thompson, John A. ;

Hwu, Wen-Jen ;

McDermott, David F. ;

Brookes, Melissa ;

Tosolini, Alessandra ;

Ebbinghaus, Scot ;

Yang, Zijiang ;

Gause, Christine K. ;

Perini, Rodolfo F. ;

Ribas, Antoni .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[6] Interleukin 2: from immunostimulation to immunoregulation and back again [J].

Bachmann, Martin F. ;

Oxenius, Annette .

EMBO REPORTS, 2007, 8 (12) :1142-1148

[7] Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial [J].

Baek, Soyoung ;

Kim, Choung-Soo ;

Kim, Sung-Bae ;

Kim, Yong-man ;

Kwon, Seog-Woon ;

Kim, YongMan ;

Kim, HyunSoo ;

Lee, Hyunah .

JOURNAL OF TRANSLATIONAL MEDICINE, 2011, 9

[8] Controllers of the immune system and a new promise for immunotherapy [J].

Banchereau, J ;

Paczesny, S ;

Blanco, P ;

Bennett, L ;

Pascual, V ;

Fay, J ;

Palucka, AK .

IMMUNE MECHANISMS AND DISEASE, 2003, 987 :180-187

[9] Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma [J].

Bedke, Jens ;

Kruck, Stephan ;

Gakis, Georgios ;

Stenzl, Arnulf ;

Goebell, Peter J. .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (05) :1201-1208

[10]

Borden EC, 1998, SEMIN ONCOL, V25, P3

← 1 2 3 4 5 6 7 8 →